On this page

Fluocinonide

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Fluocinonide
Generic name
Fluocinonide
Dosage form
Ointment
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
9
Packages
17
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Fluocinonide .05 mg/g 310364 View
Fluocinonide .5 mg/g 310364 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Ointment
Route of administration
Topical
Presentations
26

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
212976
Application type
ANDA · Abbreviated New Drug Application
Approval date
November 26, 2019
Sponsor
XIROMED
Products on application
1
Submissions recorded
1
Products approved under application 212976.
Product Trade name Form Strength Ingredient Status TE Flags
212976-001 FLUOCINONIDE OINTMENT FLUOCINONIDE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 212976.
Type No. Action Status Date Review
Original application 1 Approved November 26, 2019 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260417). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260417 HUMAN PRESCRIPTION DRUG · 20251223 HUMAN PRESCRIPTION DRUG · 20240717

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Fluocinonide Cream USP, 0.05%, Fluocinonide Cream USP, 0.05% (Emulsified Base), Fluocinonide Gel USP, 0.05% and Fluocinonide Ointment USP, 0.05% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Fluocinonide Cream USP, 0.05%, Fluocinonide Cream USP, 0.05% (Emulsified Base), Fluocinonide Gel USP, 0.05% and Fluocinonide Ointment USP, 0.05% are generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS The topical corticosteriods are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Itching Irritation Dryness Folliculitis Hypertrichosis Acneiform Eruptions Hypopigmentation Perioral Dermatitis Allergic Contact Dermatitis Maceration of the Skin Secondary Infection Skin Atrophy Striae Miliaria To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc., at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Fluocinonide Cream USP, 0.05%, Fluocinonide Cream USP, 0.05% (Emulsified Base), Fluocinonide Gel USP, 0.05% and Fluocinonide Ointment USP, 0.05% are intended for topical administration. The active component in each is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6α,11β,16α)-. It has the following chemical structure: Fluocinonide Cream USP, 0.05% contains fluocinonide 0.5 mg/g in a specially formulated cream base consisting of citric acid, glycerin, 1,2,6-hexanetriol, polyethylene glycol-3350, polyethylene glycol-8000, propylene glycol and stearyl alcohol. This white cream vehicle is greaseless, non-staining, anhydrous and completely water miscible. The base provides emollient and hydrophylic properties. Fluocinonide Cream USP, 0.05% (Emulsified Base) contains fluocinonide 0.5 mg/g in a water-washable aqueous emollient base of cetyl alcohol, citric acid (anhydrous), mineral oil, polysorbate 60, propylene glycol, purified water, sorbitan monostearate, stearyl alcohol and white petrolatum. Fluocinonide Gel USP, 0.05% contains fluocinonide 0.5 mg/g in a specially formulated gel base consisting of carbomer 940, edetate disodium, propyl gallate, propylene glycol, sodium hydroxide (to adjust pH) and purified water. This clear, colorless, thixotropic vehicle is greaseless, non-staining and completely water miscible. Fluocinonide Ointment USP, 0.05% contains fluocinonide 0.5 mg/g in a specially formulated ointment base consisting of glyceryl monostearate, propylene carbonate, propylene glycol, white petrolatum and white wax. It provides the occlusive and emollient effects desirable in an ointment. In the Fluocinonide Cream USP, 0.05%, Fluocinonide Gel USP, 0.05%, and Fluocinonide Ointment USP, 0.05% formulations, the active ingredient is totally in solution. Chemical Structure

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Fluocinonide Cream USP, 0.05% is supplied in 15 g (NDC 51672-1253-1), 30 g (NDC 51672-1253-2), 60 g (NDC 51672-1253-3) and 120 g (NDC 51672-1253-4) tubes. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Fluocinonide Cream USP, 0.05% (Emulsified Base) is supplied in 15 g (NDC 51672-1254-1), 30 g (NDC 51672-1254-2) and 60 g (NDC 51672-1254-3) tubes. Store at controlled room temperature. Avoid excessive heat, above 40°C (104°F). Fluocinonide Gel USP, 0.05% is supplied in 15 g (NDC 51672-1279-1), 30 g (NDC 51672-1279-2) and 60 g (NDC 51672-1279-3) tubes. Store at 20°- 25°C (68°- 77°F) [see USP Controlled Room Temperature]. Fluocinonide Ointment USP, 0.05% is supplied in 15 g (NDC 51672-1264-1), 30 g (NDC 51672-1264-2) and 60 g (NDC 51672-1264-3) tubes. Store at 20°-25°C (68°-77°F). Avoid temperature above 30°C (86°F).

Adverse event reports

Source: openFDA FAERS
5,595
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: FLUOCINONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
63629-2337-1 63629-2337 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-2337-1) / 60 g in 1 TUBE April 19, 2021
63629-2338-1 63629-2338 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-2338-1) / 30 g in 1 TUBE April 19, 2021
63629-2339-1 63629-2339 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-2339-1) / 15 g in 1 TUBE April 19, 2021
72162-1972-2 72162-1972 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1972-2) / 15 g in 1 TUBE February 2, 2024
72162-1972-3 72162-1972 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1972-3) / 30 g in 1 TUBE February 2, 2024
72162-1972-6 72162-1972 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1972-6) / 60 g in 1 TUBE February 2, 2024
68071-2202-5 68071-2202 NuCare Pharmaceuticals,Inc. 1 TUBE in 1 CARTON (68071-2202-5) / 15 g in 1 TUBE June 25, 2020
68788-8554-6 68788-8554 Preferred Pharmaceuticals Inc. 1 TUBE in 1 CARTON (68788-8554-6) / 60 g in 1 TUBE November 20, 2023
51672-1264-1 51672-1264 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1264-1) / 15 g in 1 TUBE June 30, 1999
51672-1264-2 51672-1264 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1264-2) / 30 g in 1 TUBE June 30, 1999
51672-1264-3 51672-1264 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1264-3) / 60 g in 1 TUBE June 30, 1999
0093-0264-15 0093-0264 Teva Pharmaceuticals USA, Inc. 1 TUBE in 1 CARTON (0093-0264-15) / 15 g in 1 TUBE May 1, 1992
0093-0264-30 0093-0264 Teva Pharmaceuticals USA, Inc. 1 TUBE in 1 CARTON (0093-0264-30) / 30 g in 1 TUBE May 1, 1992
0093-0264-92 0093-0264 Teva Pharmaceuticals USA, Inc. 1 TUBE in 1 CARTON (0093-0264-92) / 60 g in 1 TUBE May 1, 1992
70700-146-15 70700-146 Xiromed LLC 1 TUBE in 1 CARTON (70700-146-15) / 15 g in 1 TUBE December 9, 2019
70700-146-16 70700-146 Xiromed LLC 1 TUBE in 1 CARTON (70700-146-16) / 30 g in 1 TUBE December 9, 2019
70700-146-17 70700-146 Xiromed LLC 1 TUBE in 1 CARTON (70700-146-17) / 60 g in 1 TUBE December 9, 2019
63629-2337 63629-2337 Bryant Ranch Prepack — December 9, 2019
63629-2338 63629-2338 Bryant Ranch Prepack — December 9, 2019
63629-2339 63629-2339 Bryant Ranch Prepack — December 9, 2019
72162-1972 72162-1972 Bryant Ranch Prepack — December 9, 2019
68071-2202 68071-2202 NuCare Pharmaceuticals,Inc. — May 1, 1992
68788-8554 68788-8554 Preferred Pharmaceuticals Inc. — November 20, 2023
51672-1264 51672-1264 Sun Pharmaceutical Industries, Inc. — June 30, 1999
0093-0264 0093-0264 Teva Pharmaceuticals USA, Inc. — May 1, 1992
70700-146 70700-146 Xiromed LLC — December 9, 2019

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.